Incyte Corporation
A biopharmaceutical company that develops treatments for blood cancers and other cancers (JAKAFI, ICLUSIG), plus creams for skin conditions like vitiligo and eczema (OPZELURA). Founded in 1991 in Palo Alto, it began as a genomics pioneer selling its LifeSeq gene database to researchers before pivoting to making its own drugs. Its name blends "insight" with "cyt," the Greek root for cell — a nod to its genome-sequencing roots.
Granted 35.6K
Sold 187.5K
Granted 87.5K · Sold 56.0K
Granted 125.0K
Granted 49.4K · Sold 43.5K
Sold 10.9K
Sold 5.8K
Granted 8.9K · Sold 3.1K
Granted 7.4K · Sold 58.3K
Granted 2.6K · Sold 6.1K
Granted 26.3K
Granted 17.4K · Sold 15.0K
Granted 16.6K
Granted 5.4K · Sold 8.8K
Granted 2.4K
Granted 1.6K
Granted 1.6K
Granted 1.6K
Granted 9.5K
Granted 9.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 10 transactions | — | 121.83M | 35.6K | — | — |
| Hoppenot HerveDirector · 2 transactions | -36.8% | 326.8K | — | — | 187.5K |
| Cagnoni Pablo JPresident, Global Head of R&D · 11 transactions | +10.9% | 240.8K | 87.5K | — | 56.0K |
| Meury WilliamChief Executive Officer, Director, President · 1 transaction | +346.3% | 161.1K | 125.0K | — | — |
| Stein Steven HCMO & Head of Late-Stage Dev. · 10 transactions | -23.9% | 78.3K | 49.4K | — | 43.5K |
| Issa Mohamed KhairieEVP, Head of US Oncology · 2 transactions | -22.4% | 66.1K | — | — | 10.9K |
| Mayes Patrick AEVP & Chief Scientific Officer · 3 transactions | -10.9% | 60.0K | — | — | 5.8K |
| Heeson LeeEVP, Head of Incyte Intl · 4 transactions | +16.1% | 38.0K | 8.9K | — | 3.1K |
| Morrissey Michael JamesEVP, Head of Tech. Operations · 8 transactions | -60.5% | 34.1K | 7.4K | — | 58.3K |
| Denton Sheila A.EVP & General Counsel · 14 transactions | -20.6% | 26.6K | 2.6K | — | 6.1K |
| Upadhyay SuketuEVP & Chief Financial Officer · 1 transaction | — | 26.3K | 26.3K | — | — |
| Clancy Paul JDirector · 6 transactions | +10.6% | 25.4K | 17.4K | — | 15.0K |
| Bienaime Jean JacquesDirector · 3 transactions | +17.2% | 24.4K | 16.6K | — | — |
| Tray ThomasPrincipal Accounting Officer · 9 transactions | -2.2% | 23.8K | 5.4K | — | 8.8K |
| Harrigan EdmundDirector · 4 transactions | +12% | 22.8K | 2.4K | — | — |
| Fouse Jacqualyn ADirector · 1 transaction | +8.5% | 21.0K | 1.6K | — | — |
| High Katherine ADirector · 1 transaction | +12.3% | 15.0K | 1.6K | — | — |
| Trotta MatteoEVP, GM, Dermatology US · 1 transaction | +52.6% | 14.9K | — | — | — |
| Brawley Otis WDirector · 1 transaction | +14.6% | 12.9K | 1.6K | — | — |
| Basi Ramitpal KEVP, Human Resources · 1 transaction | +69% | 11.0K | — | — | — |
| Hoffman Richard A.EVP & General Counsel · 1 transaction | — | 9.5K | 9.5K | — | — |
| Gardner David HEVP, Chief Strategy Officer · 1 transaction | — | 9.4K | 9.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -395.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.